Akoya (AKYA) Misses Q4 EPS by 16c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Akoya Reports Fourth Quarter and Full Year 2021 Operating Results and Provides 2022 Financial Outlook
March 14, 2022 4:05 PM EDTQ4 2021 revenue $16.2 million and FY 2021 revenue $54.9 million
FY 2022 revenue guidance $69 - 71 million
MARLBOROUGH, Mass., March 14, 2022 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (Akoya), The Spatial Biology Company®, today announced its financial results for the fourth quarter and full year ending December 31, 2021.
Our strong finish to 2021 demonstrates the continued and accelerating adoption of our leading spatial biology solutions and is a result of sound execution of our financial and strategic plans, said Brian McKelligon, Chief Executive Officer, Akoya Biosciences. We set another record in quarterly revenue, grew our installed base to nearly 700... More
